Indalo Therapeutics is a biopharmaceutical company discovering and developing novel integrin antagonists for patients suffering from serious fibrotic diseases. Our scientific leadership team leverages deep target knowledge and decades of antifibrotic drug development expertise. We have experienced first-hand the satisfaction of bringing hope to patients suffering from chronic fibrotic diseases through the successful development and approval of Esbriet®, an innovative drug for pulmonary fibrosis.
We have completed a rigorous set of GLP toxicology and safety-pharmacology studies with our lead candidate IDL-2965 and have designed an efficient and adaptive Phase 1 clinical program to enable assessment of safety, pharmacokinetics, and biomarker-based proof of mechanism in liver fibrosis and pulmonary fibrosis patients. The first healthy volunteer is slated to be dosed in early 2019.